Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.

Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.

Item
http://www.wikidata.org/entity/Q33387073
Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting.Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumabIndirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy.Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries.Cost comparison of second-line treatment options for late stage non-small-cell lung cancer: cost analysis for Italy.Cost effectiveness of first-line treatment with doxorubicin/ifosfamide compared to trabectedin monotherapy in the management of advanced soft tissue sarcoma in Italy, Spain, and sweden.Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis.Present and future therapeutic options for locally advanced and metastatic renal cell carcinoma.Cost-effectiveness of sunitinib in metastatic renal cell carcinoma.Emerging antiangiogenics for renal cancer.A review of economic impact of targeted oral anticancer medications.A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France.Economic Analysis Comparing Dalteparin to Vitamin K Antagonists to Prevent Recurrent Venous Thromboembolism in Patients With Cancer Having Renal Impairment.Comment on 'costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib'.Regarding: 'Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib'.Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma.Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria.
P2860

Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.

Item
http://www.wikidata.org/entity/Q33387073
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Costs of managing adverse even ...... pha2a compared with sunitinib.
@ast
Costs of managing adverse even ...... pha2a compared with sunitinib.
@en
type
label
Costs of managing adverse even ...... pha2a compared with sunitinib.
@ast
Costs of managing adverse even ...... pha2a compared with sunitinib.
@en
prefLabel
Costs of managing adverse even ...... pha2a compared with sunitinib.
@ast
Costs of managing adverse even ...... pha2a compared with sunitinib.
@en
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P6179
P698
P921
P932
P356
P1433
P1476
Costs of managing adverse even ...... pha2a compared with sunitinib.
@en
P2093
P2860
P2888
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P6179
P698
P921
P932